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The role of inflammation in obesity-related pathol-
ogies is well established. We investigated the thera-
peutic potential of LipoxinA4 (LXA4:5(S),6(R),15(S)-
trihydroxy-7E,9E,11Z,13E,-eicosatetraenoic acid)
and a synthetic 15(R)-Benzo-LXA4-analog as inter-
ventions in a 3-month high-fat diet (HFD; 60% fat)-
induced obesity model. Obesity caused distinct
pathologies, including impaired glucose tolerance,
adipose inflammation, fatty liver, and chronic
kidney disease (CKD). Lipoxins (LXs) attenuated
obesity-induced CKD, reducing glomerular expan-
sion, mesangial matrix, and urinary H2O2. Further-
more, LXA4 reduced liver weight, serum alanine-
aminotransferase, and hepatic triglycerides. LXA4
decreased obesity-induced adipose inflammation,
attenuating TNF-a and CD11c+ M1-macrophages
(MFs), while restoring CD206+ M2-MFs and
increasing Annexin-A1. LXs did not affect renal or
hepatic MFs, suggesting protection occurred via
attenuation of adipose inflammation. LXs restored
adipose expression of autophagy markers LC3-II
and p62. LX-mediated protection was demonstrable
in adiponectin/ mice, suggesting that the mecha-
nism was adiponectin independent. In conclusion,
LXs protect against obesity-induced systemic dis-
ease, and these data support a novel therapeutic
paradigm for treating obesity and associated
pathologies.INTRODUCTION
Obesity and the metabolic syndrome represent a global health
problem, particularly due to associated co-morbidities. Obesity
is an independent risk factor for systemic diseases, including
diabetes, liver cirrhosis, and chronic kidney disease (CKD) (Bo¨r-
geson and Sharma, 2013; Ix and Sharma, 2010). Metabolism is
closely linked to the immune system, and chronic, non-resolving
inflammation is considered a driving force of obesity-related
pathologies. Prolonged and excessive nutrient overload results
in chronic activation of the immune system and associated
inflammation (Donath et al., 2013).
In addition to low-grade systemic inflammation, obesity is
associated with significant adipose inflammation (Donath et al.,
2013; Wen et al., 2011). The initiating processes for adipose
inflammation are not entirely understood, but hypoxia due to
adipose hypertrophy and a shift of macrophage (MF) phenotype
from anti-inflammatory M2 to pro-inflammatory M1 likely play
critical roles (Masoodi et al., 2015; McNelis and Olefsky, 2014).
M1 MFs produce significant amounts of pro-inflammatory cyto-
kines and chemokines, as do adipocytes due to FFA ligation or
as a result of adipocyte apoptosis. There is a growing recognition
that adipose inflammation culminates in systemic disease, as it
exaggerates systemic inflammation and reduces the production
of the protective adipokine adiponectin (Bo¨rgeson and Sharma,
2013). Reduced adiponectin has been found to be associated
with organ dysfunction in mice and humans and contributes
directly to liver (Finelli and Tarantino, 2013) and kidney diseases
(Sharma, 2009; Sharma et al., 2008).
Results of recent studies highlight the possibility that failed
resolution of inflammation may underlie the pathogenesis of
chronic inflammatory disorders, such as in metabolic syndromeCell Metabolism 22, 125–137, July 7, 2015 ª2015 Elsevier Inc. 125
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Figure 1. Lipoxins Attenuated Adipose Inflammation and Shift Adipose Macrophage Phenotype toward Resolution in Vivo
(A) Schematic illustration of the protocol: C57BL/6 mice fed a standard-fat diet (SFD: 10% fat) or a high-fat diet (HFD: 60% fat) for 12 weeks were treated with
vehicle, LXA4 (5 ng/g), or BenzoLXA4 (1.7 ng/g) three times per week between weeks 5 and 12.
(B) WAT macrophage (MF) phenotype was analyzed by flow cytometry. Leukocytes were identified as inflammatory M1 MFs (CD11c+ of CD45+F480hiCD11bhi
cells) versus anti-inflammatory M2 MFs (CD206+ of CD45+F480hiCD11bhi cells). Representative dot plots are shown as well as quantification of both percent
positive cells and absolute cell numbers; n = 4.
(legend continued on next page)
126 Cell Metabolism 22, 125–137, July 7, 2015 ª2015 Elsevier Inc.
and diabetes (for recent review see Spite et al., 2014). Immuno-
modulation and specifically immunoresolvents are suggested as
a therapeutic strategy to overcome chronic inflammation and
disease (Bo¨rgeson and Godson, 2012; Donath, 2014; Donath
et al., 2013; Serhan, 2007; Serhan and Savill, 2005; Tabas and
Glass, 2013). Acute inflammation is orchestrated in part by
chemical autacoids in the form of peptides (cytokines, chemo-
kines) and lipid mediators (i.e., prostaglandins and leukotrienes),
which induce edema and polymorphonuclear leukocyte (PMN)
recruitment to inflammatory loci. In a physiologic state, this initial
phase is followed by resolution, characterized by the cessation
of PMN infiltration, MF-mediated efferocytosis, and the return
to tissue homeostasis (Maderna and Godson, 2009). The resolu-
tion of inflammation is regulated by specialized pro-resolving
mediators (SPMs). These include the u3-derived protectins, re-
solvins (Rvs), and maresins as well as the u6-derived Lipoxin
A4 (LXA4; 5(S),6(R),15(S)-trihydroxy-7E,9E,11Z,13E-eicosate-
traenoic acid) and Lipoxin B4 (LXB4; 5(S),14(R),15(S)-trihy-
droxy-6E,8Z,10E,12E-eicosatetraenoic acid). SPMs attenuate
PMN recruitment and induce a pro-resolving M2 phenotype.
These M2MFs produce more SPMs compared to M1MFs (Dalli
and Serhan, 2012), thus further sustaining resolution, and u3-
derived SPMs also facilitate production of u6-derived SPMs
(Fredman et al., 2014). LXA4 potently attenuates acute inflamma-
tion (Maderna and Godson, 2009) and age-associated adipose
inflammation ex vivo (Borgeson et al., 2012). Of note SPMs
have been identified in a number of human tissues and fluids
including spleen, lymph nodes (Colas et al., 2014), urine (Sasaki
et al., 2015), and white adipose tissue (WAT) (Cla`ria et al., 2013).
Importantly, whether LXA4 actively attenuates chronic inflamma-
tion remains to be addressed.
Here, we explored the therapeutic potential of LXA4 in exper-
imental obesity-induced systemic disease. Because native LXs
are chemically labile and undergo inactivation in vivo via either
dehydrogenation and/or omega-oxidation (depending on the
local environment), we also evaluated the actions of a
stable benzo-fused (15R)-stereoisomer analog, referred to as
BenzoLXA4 (Borgeson et al., 2011). We report that LXA4 and
BenzoLXA4 attenuate obesity-induced adipose inflammation
and alter the adipose M1/M2 ratio, while modulating adipose
autophagy, a driver of adipose inflammation (Martinez et al.,
2013; Stienstra et al., 2014). These actions resulted in adiponec-
tin-independent protection against obesity-induced liver and
kidney disease, demonstrating the therapeutic potential of LXs
in obesity-induced complications.
RESULTS
Lipoxins Attenuate Obesity-Induced Adipose
Inflammation and Alter the M1/M2 Ratio
Mice were subjected to a 3-month dietary regime to induce
obesity and associated liver and kidney disease (Figure 1A).
LXs were provided as interventional therapeutics, introduced
from weeks 5 to 12. Animals tolerated all treatments well. LXs(C) WAT TNF-a and IL-6 expression were analyzed by qPCR; n = 4.
(D) WAT adiponectin was analyzed by ELISA; n = 4.
(E) WAT Annexin-A1 protein was determined by western blot; a representative
presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA with Bondid not affect high-fat diet (HFD)-induced weight gain, WAT hy-
pertrophy, or adipocyte size (Figures S1A–S1C). HFD was not
associated with an increase in total WAT F4/80+ MFs, as
analyzed both by flow cytometry and immunohistochemistry
(IHC) (Figure S3). It is noteworthy that this is in contrast to other
studies (Oh et al., 2012) and may possibly be due to the control
diets. Rather than using vivarium chow, this study is conducted
using a standard fat diet (SFD) control diet containing equal pro-
tein content and matched sucrose content compared to the
HFD, which may incur important differences in MF infiltration.
Importantly, HFD-induced obesity did cause a significant in-
crease in M1/M2 ratio in visceral adipose tissue, as previously
reported (Lumeng et al., 2007). LXs shifted the MFs toward a
resolution phenotype. Specifically, LXA4 attenuated the HFD-
induced increase of the percent pro-inflammatory CD11c+ M1
MFs (p < 0.05), and LXA4 partially restored the percent anti-
inflammatory CD206+ MF population (p < 0.05) (Figure 1B). In
addition, we calculated the absolute cell numbers, as the
obesity-induced expansion ofWAT and increase in overall leuko-
cyte infiltration may mask percentage shifts of cellular popula-
tions. Interestingly, the effect of LXA4 on CD206
+ M2 MFs is
amplified when comparing the absolute cell numbers, whereas
the attenuation of CD11c+ M1 is not apparent (Figure 1B). In
addition to switching MF phenotype, LXA4 attenuated obesity-
induced expression of the pro-inflammatory cytokine TNF-a
(Figure 1C). WAT expression of IL-10 remained unaltered (data
not shown), and IL-6 was elevated with HFD, but was not
reduced with treatment (Figure 1C). No significant changes
were found in the CD8+ and CD4+ T cell populations, nor in
CD19+ B cell infiltration (data not shown). However, it is impor-
tant to note that we were unable to include intracellular markers
in this flow cytometry panel, which prevented T cell subset char-
acterization, e.g., T-regs, TH1, and TH2 ratio. Visceral adipose
tissue adiponectin levels were measured by ELISA and in
accordance with previous reports (Neuhofer et al., 2013); the
HFD led to reduced secretion of adiponectin (p < 0.05). Treat-
ment with LXs partially restored adiponectin in comparison
with the control groups (SFD, 84 ± 9; HFD, 47 ± 7; HFD+LXA4,
70 ± 9; HFD+BenzoLXA4, 64 ± 12 ng/ml) (Figure 1D). However,
there was no effect of LXs on the degree of WAT hypertrophy
(Figures S1B and S1C). Annexin-A1 (AnxA1) is a glucocorticoid
effector (Perretti and D’Acquisto, 2009), and AnxA1 deficiency
promotes HFD-induced adiposity and insulin resistance (Aka-
sheh et al., 2013). Our study confirms that WAT AnxA1 ex-
pression is increased in obese mice (Akasheh et al., 2013),
and LXA4 treatment significantly increased AnxA1 expression
(Figure 1E).
Adipose tissue is heterogeneous and comprised of numerous
cell types, where adipocytes and MFs are the major mediators
of inflammation and disease (McNelis and Olefsky, 2014).
Both cell types express the LXA4 receptor (ALX/FPR2) and
are susceptible to the anti-inflammatory actions of LXA4 (Bor-
geson et al., 2012). To clarify the cellular targets affected by
LXs in this model, we designed a similar in vitro systemblot is shown and densitometry quantification of n = 3 experiments. Data are
ferroni correction.
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Figure 2. Lipoxins Attenuated Adipose
Inflammation and Shift Adipose Macro-
phage Phenotype toward Resolution in Vitro
J774 macrophages (MFs), constitutively ex-
pressing an M1 phenotype, were incubated with
vehicle, 1 nM LXA4, or 10 pM BenzoLXA4 for 16 hr.
MF phenotype was analyzed by flow cytometry,
and supernatants were collected. Serum-starved
hypertrophic 3T3-L1 adipocytes were treated with
vehicle, 1 nM LXA4, or 10 pM BenzoLXA4, or
alternatively with MF-conditioned supernatants,
as indicated. Following 24-hr incubation, adipo-
cyte supernatants were collected and analyzed
by ELISA.
(A) J774 MF phenotype was analyzed by flow
cytometry, and representative dot plots are shown
of anti-inflammatory M2 (CD206+) MFs and pro-
inflammatory M1 (CD11c+) MFs, with respective
quantification below; n = 3.
(B) Adipocyte cytokine production was analyzed
by ELISA; n = 3. Data are presented as mean ±
SEM; n = 3. *p < 0.05, **p < 0.01, ***p < 0.001;
ANOVA with Bonferroni correction.comprised of inflammatory MFs and hypertrophic adipocytes,
where the latter resemble the adipocyte biology seen in
obesity (Yoshizaki et al., 2012). The aim was to investigate
whether LXs exert their protective effects via altering of MF
phenotype and/or adipocyte cellular function. First, we charac-
terized the ability of LXs to shift MF phenotype in vitro, using
the constitutively M1-activated J774 cell line, which presents
with high CD11c+ and low CD206+ expression (Figure 2).
Both LXA4 and BenzoLXA4 significantly increased CD206
+
expression in vitro (p < 0.05) (Figure 2A). Interestingly, J774 ex-
pressed two distinct CD11c+ populations: CD11clow and
CD11chigh. Similarly to the in vivo scenario, LXA4 attenuated
CD11c+ expression, specifically targeting the CD11clow popula-
tion (p < 0.05) (Figure 2A).128 Cell Metabolism 22, 125–137, July 7, 2015 ª2015 Elsevier Inc.We subsequently stimulated hypertro-
phic adipocytes either directly with
vehicle, LXA4, or BenzoLXA4, or alterna-
tively with MF-conditioned media from
J774 cells treated with either vehicle or
LXs, as illustrated in Figure 2B. In accor-
dance with previous research (Borgeson
et al., 2012), LXA4 significantly attenuated
adipocyte IL-6 secretion (Figure 2B). Of
note, the hypertrophic adipocytes did
not produce detectable levels of TNF-a
or IL-10 (data not shown). In contrast,
the J774 MFs secreted high levels of
TNF-a (Figure 2B), but not IL-6 or IL-10
(data not shown). When co-culturing adi-
pocytes with MF-conditioned media,
LXA4 treatment attenuated MF-induced
TNF-a production (p < 0.05), although
IL-6 remained unaltered (Figure 2B),
similar to findings in our in vivo study (Fig-
ure 1C). Importantly, the MF-conditioned
media appeared to increase adipose IL-6production, which appears to have masked the basal LXA4-
mediated attenuation of IL-6 secretion (Figure 2B).
Lipoxins Modulate Obesity-Induced Adipose Autophagy
Obesity causes excessive upregulation of WAT autophagy,
which is linked to adipose stress and inflammation (Stienstra
et al., 2014). We analyzed two of the main markers of autophagy
and autophagic flux: LC3 and p62. LC3 is an ubiquitin-like protein
involved in the biogenesis of autophagosome. It is cleaved from
the microtubular network to form LC3-I, which is lipidated by the
Atg12-Atg5-Atg16L complex to generate LC3-II. Lipidated LC3-II
is incorporated into the phagophore during its formation and
guides the autophagosome. Conversion of LC3-I to LC3-II is a
hallmark of autophagy induction, and the LC3-II:LC3-I ratio is
AB
Figure 3. Lipoxins Modulate Obesity-Induced
Adipose Autophagy
C57BL/6 mice, fed a standard-fat diet (SFD: 10% fat)
or a high-fat diet (HFD: 60% fat) for 12 weeks, were
treated with vehicle, LXA4 (5 ng/g), and BenzoLXA4
analog (1.7 ng/g) three times per week between
weeks 5 and 12.
(A) Representative western blots are shown of adi-
pose autophagy markers (p62 and LC3-II protein,
normalized to b-Actin). Quantification is expressed as
a fold ratio to control (right panels; n = 4).
(B) Representative immunofluorescence staining of
WAT LC3-II (green) and p62 (red) is shown (n = 3).
Data are presented as mean ± SEM. *p < 0.05, **p <
0.01, ***p < 0.001; ANOVAwith Bonferroni correction.used to assess autophagy. We observed a reduction in the WAT
LC3-II levels in obese mice, indicating reduced expression or
enhanced degradation of LC3-II (Figure 3A). In agreement with
previous reports of obesity-induced enhancement of autophagy
in WAT, we envisage that the reduced levels of LC3-II are a
consequence of enhanced lysosomal degradation due to higher
autophagic flux. Similarly, we observed reduced WAT p62 levels
in HFD mice (Figure 3A). p62/sequestosome1 (SQSTM1) is a
ubiquitin-binding scaffold protein serving as an adaptor for the
recruitment of ubiquitinated protein aggregates to the autopha-
gosome. Similar to LC3-II, p62 accumulates as autophagy is in-
hibited and decreases when autophagy is induced. Interestingly,
LXs restored the obesity-induced reduction in the levels of LC3-II
(p < 0.05) and p62 (p < 0.05) (Figure 3A). These findings are
confirmed by immunofluorescence staining of autophagy
markers p62 and LC3-II (Figure 3B), indicating that LXs downre-
gulated obesity-induced autophagy. To gain mechanistic in-
sights into the mechanism for LX’s regulation of autophagy, we
performed WB analysis to determine mTOR and AMPK activity
and expression. AMPK promotes autophagy by promoting Ulk1
phosphorylation at Ser317 and Ser777, and, conversely, mTOR
inhibits autophagy by inhibiting Ulk1 by phosphorylation at Ser
757. Surprisingly, LXA4 or BenzoLXA4 did not affect mTOR and
AMPK significantly (data not shown), suggesting that LXs regu-Cell Metabolism 22, 1late autophagy independent of mTOR and
AMPK. It is noteworthy that p62/SQSTM1
has been identified as a key protein promot-
ing lipid metabolism and limiting inflamma-
tion in the recently identified ‘‘metabolically
activated’’ MFs (mMe-MFs) (Kratz et al.,
2014). Thus, LX-mediated restoration of
p62 may correlate with a restoration not
only of M1/M2 phenotype, but also of the
mMe-MF population.
Lipoxins Attenuate Obesity-Induced
Liver Disease
Obesemice presentedwith increased abso-
lute liver weight (p < 0.05) compared to SFD
mice. Interestingly, liver expansion was
attenuated by LXA4 (p < 0.01) (Figure 4A),
even though the total body weight remained
unalteredwith the LX treatment (FigureS1A).In light of this finding, we further investigated serum alanine
aminotransferase (ALT) levels, a cardinal sign of liver injury.
Obesity increased ALT by 3.15-fold (p < 0.05), which was attenu-
ated by both LXA4 and BenzoLXA4 to basal levels (p < 0.05) (Fig-
ure 4B). Circulating and hepatic triglyceride (TG) levels were
significantly increased during obesity. Interestingly, LXA4 (p <
0.05) and BenzoLXA4 (p < 0.01) attenuated liver TG deposition,
although serum TGs remained unaltered (Figure 4C). HFD
increased serum cholesterol E, but no significant effects were
seenwith LXA4 (data not shown).Obesitydid not increasehepatic
MF infiltration, assessed throughF4/80+ staining, andnoobvious
changes were observed with LX treatment (Figure 4D). Further-
more, hepatic gene expression of inflammatory cytokines,
including TNF-a, IL-6, and anti-inflammatory cytokine IL-10,
was assessed, but no significant differences were observed
withHFD (data not shown). Finally,we assessed livermorphology
using Ki67 and H&E staining; no differences in proliferation were
detected (data not shown), but obesity inducedsomemild vacuo-
lization, which appeared attenuated by LX treatment (Figure 4E).
Lipoxins Attenuate Obesity-Induced CKD
Obese mice presented with CKD, as evidenced by increased
albuminuria, confirming that the model reflects obesity-induced
CKD (Figure 5A). LXA4 significantly attenuated obesity-induced25–137, July 7, 2015 ª2015 Elsevier Inc. 129
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Figure 4. Lipoxins Attenuate Obesity-Induced
Liver Injury
C57BL/6 mice, fed a standard-fat diet (SFD: 10% fat) or
a high-fat diet (HFD: 60% fat) for 12weeks, were treated
with vehicle, LXA4 (5 ng/g), or BenzoLXA4 (1.7 ng/g)
three times per week between weeks 5 and 12.
(A–C) (A) Liver weight was analyzed at harvest; n = 10.
To further assess liver injury we analyzed (B) serum
alanine aminotransferase (ALT) and (C) hepatic and
serum TG content; n = 4.
(D and E) Representative images of hepatic F4/80+
macrophages and H&E staining are shown; n = 3. Data
are presented as mean ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001; ANOVA with Bonferroni correction.albuminuria, demonstrating protection against disease (Figure
5A). LXA4 attenuated obesity-induced urinary H2O2, demon-
strating protection against renal injury, possibly by attenuation
of free radical production (Figure 5B). HFD-induced glomerular
expansion and mesangial matrix expansion were significantly
attenuatedbyLXA4andBenzoLXA4 (Figure5D).To furtheranalyze
tubulointerstitial injury and fibrosis, collagen deposition was
assessed using Sirius Red staining, specifically detecting newly
deposited collagen. Interestingly, HFD-induced tubulointerstitial
collagen deposition was significantly attenuated by LXA4 and
BenzoLXA4 (Figure 5E). Renal MF infiltration was investigated
by flow cytometry. HFD increased the ratio of CD11c+ M1 MFs,
butCD206+M2MFswereonly detectedatminimal levels. Inaddi-
tion, LXs did not affect HFD-induced renal MF infiltration in this
model, as assessed by flow cytometry analysis (data not shown).
Lipoxin-Mediated Protection Is Independent of
Adiponectin
Obesity-induced impairment of the adiponectin/AMPK pathway
causes both liver and kidney disease (Polyzos et al., 2010;130 Cell Metabolism 22, 125–137, July 7, 2015 ª2015 Elsevier Inc.Sharma, 2009; Sharma et al., 2008). We noted
a trend toward increased WAT adiponectin
levels in LX-treated mice (Figure 1D), and
thus we evaluated whether the LX-mediated
hepatic and reno-protective effects were
mediated via the adiponectin axis by
comparing the HFD-induced pathology
observed in the C57BL/6J wild-type (WT)
(Figure 5) versus adiponectin/ knockout
(KO) mice (Figure 6). The adiponectin/
mice were more susceptible to obesity-
induced kidney and liver disease, as indicated
by increased albuminuria (p < 0.01, ##), urine
H2O2 (p < 0.05, #), and serum ALT (p < 0.05, #)
(Figures 6A–6C). LXs also displayed reno-
protective actions in adiponectin/ mice, as
demonstrated by a reduction in albuminuria
(p < 0.05, *), and both LXA4 (p < 0.001, ***)
and BenzoLXA4 (p < 0.01, **) attenuated
HFD-induced urine H2O2 in the mice lacking
the adiponectin gene (Figures 6A and 6B).
Similarly, LXs significantly reversed the
obesity-induced increase of serum ALT in
the adiponectin/ mice (Figure 6C). These
findings demonstrate unique properties of LXA4 compared to
other u3-derived SPMs, which regulate obesity via direct action
on adiponectin (Cla`ria et al., 2012; Rius et al., 2014).
As anticipated, obese animals displayed decreased sensitivity
to insulin-stimulated glucose uptake. LXA4 and BenzoLXA4 did
not rescue obesity-induced impairment of glucose tolerance in
C57BL/6J mice, suggesting that protection against liver disease
and CKD occurs independent of rescued insulin sensitivity (Fig-
ure 6D, WT data). Adiponectin/ mice displayed exaggerated
impairment of glucose tolerance compared to respective WT
control (p < 0.001, ###) (Figure 6D). LXs restored HFD-induced
impairment of glucose uptake, and LXA4 attenuated fasting
blood glucose in the KO strain (Figure 6D). To investigate our
findings further in vitro, hypertrophic adipocytes were used as
an experimental model of obesity (Yoshizaki et al., 2012). As
described, adipocytes were incubated with vehicle, LXA4,
BenzoLXA4, or alternatively with MF-conditioned media from
J774 cells treated with either vehicle or LXs. The LXs did
not attenuate basal adiponectin production in hypertrophic adi-
pocytes (Figure 6E), although LXA4 attenuates other cellular
Figure 5. Lipoxins Attenuate Obesity-Induced CKD
C57BL/6 mice, fed a standard-fat diet (SFD: 10% fat) or a high-fat diet (HFD: 60% fat) for 12 weeks, were treated with vehicle, LXA4 (5 ng/g), or BenzoLXA4
(1.7 ng/g) three times per week between weeks 5 and 12. At 1 week prior to harvest, 24-hr urine samples were collected. Parameters of renal injury, including (A)
albuminuria and (B) urine hydrogen peroxide (H2O2)/creatinine and (C) renal hypertrophy were assessed; n = 10.
(D and E) (D) Glomerular expansion and matrix deposition were assessed by periodic acid-Schiff and (E) tubulointerstitial collagen by Sirius Red; n = 5. Data are
presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA with Bonferroni correction.
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Figure 6. Lipoxin-Mediated Protection of Obesity-Induced Pathology Is Independent of Adiponectin
C57BL/6 or adiponectin/mice, fed a standard-fat diet (SFD: 10% fat) or a high-fat diet (HFD: 60% fat) for 12 weeks, were treated with vehicle, LXA4 (5 ng/g), or
BenzoLXA4 (1.7 ng/g) three times per week between weeks 5 and 12. Parameters of renal injury, including (A) albuminuria and (B) urine hydrogen peroxide (H2O2)/
creatinine were analyzed; n = 10.
(C) Serum alanine aminotransferase (ALT) was analyzed; n = 4.
(D) Glucose tolerance was assessed over 120 min 1 week prior to harvest. The area under curve (AUC) was calculated for respective groups and used for
statistical analysis, as well as basal fasting glucose; n = 10.
(E) Hypertrophic adipocytes were incubated with vehicle, LXA4 (1 nM), or BenzoLXA4 (10 pM) for 24 hr. Alternatively, adipocytes were incubated for 24 hr with
supernatants fromMFs pretreated with vehicle, LXA4 (1 nM), or BenzoLXA4 (10 pM). Following respective treatment, the adipocyte supernatants were collected,
and cytokine production was analyzed by ELISA; n = 3.
(legend continued on next page)
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responses in this in vitro system, e.g., basal IL-6 production (Fig-
ure 2B). LXA4 did not rescue MF-induced attenuation of adipose
adiponectin production (Figure 6E), although LXA4 attenuated
MF-induced TNF-a in this experimental setup (Figure 2B).
Finally, we investigated endogenous LXA4 production in SFD-
and HFD-treated WT and adiponectin/ mice (Figures 6F and
6G). Using LM-metabololipidomics (Figure S4), endogenous
LXA4 was identified and quantified at biologically relevant
amounts (5.7 ± 1.1 pg/100 mg tissue) (Krishnamoorthy et al.,
2010), which are comparable to levels of eicosanoids reported
by others, e.g., LTB4 (0.7 pg/100 mg tissue) (Li et al., 2015).
We also identified mediators from the DHA, EPA, and AA bioac-
tive metabolomes including RvD1 (4.2 ± 1.0 pg/100 mg tissues),
RvD5 (1.6 ± 0.4 pg/100 mg tissues), and maresin 1 (1.9 ± 0.3 pg/
100 mg tissues). These were not significantly altered in either
condition, although a trend toward reduced LXB4 levels was
observed in obese animals, which will be interesting to in-
vestigate further in future studies. Of note, HFD administration
reduced LXA4 levels in adipose tissue (WT, SFD 6.1 ± 2.4;
versus HFD, 4.3 ± 1.3 pg/100 mg tissue) (Figure 6F). We also
found a reduction in LXA4 levels between lean WT and lean
adiponectin/ mice, although in both cases the difference did
not reach statistical significance. However, the adiponectin/
mice displayed a trend of increased endogenous LXA4 produc-
tion following HFD treatment (KO, SFD 3.8 ± 1.2; versus HFD,
8.8 ± 4.2 pg/100 mg tissue) (Figure 6F). When comparing the
fold changes between lean and obese animals in respective
mouse strains, it became apparent that obesity significantly
increased endogenous LXA4 production in the adiponectin
/
group (Figure 6G; p < 0.05).
DISCUSSION
Obesity is an independent risk factor for serious pathological
conditions, including diabetes, liver disease, and CKD. Adipose
inflammation appears to be the common denominator of
obesity-related pathologies (Donath and Shoelson, 2011;
McNelis and Olefsky, 2014). Promoting the resolution of adipose
inflammation is therefore a potential therapeutic approach that
could alleviate obesity-associated organ dysfunction (Bo¨rgeson
and Godson, 2012; Cla`ria et al., 2012; Donath, 2014; Donath
et al., 2013; Spite et al., 2014; Tabas and Glass, 2013). The re-
sults presented here demonstrate that LXA4 attenuates
obesity-associated adipose inflammation and thereby alleviates
liver and kidney diseases associated with obesity.
LXs rescued HFD-induced kidney and liver disease, and the
key mechanism of action appeared to be the attenuation of
visceral WAT inflammation. In contrast to other studies (Oh
et al., 2012) we do not report an increase in total WAT F4/80+
MFs in HFD versus SFD. Importantly, we observed an obesity-
induced shift of the MF phenotype from M1 (CD11c+) to M2
(CD206+). The LXA4-induced shift in WAT MF phenotype corre-
lated with other attributes of resolution, such as attenuation of
the inflammatory cytokine TNF-a. These data may be compared(F) The endogenous adipose LXA4 production was assessed by LC-MS/MS in ve
(G) The HFD-induced fold increase of endogenous LXA4 production was calcula
*p < 0.05, **p < 0.01, ***p < 0.001. Statistically significant differences between
#p < 0.05, ##p < 0.01, ### p < 0.001; ANOVA with Bonferroni correction.with other in vivo models, where LXA4 promotes an M1-to-M2
MF polarization in a mouse air-pouch model of inflammation
(Vasconcelos et al., 2015). Indeed, LXA4 may attenuate the pro-
inflammatory M1 MF phenotype by modulating IkBa degrada-
tion, NF-kB translocation, and IKK expression, resulting in
suppressed NF-kB activation (Huang et al., 2014; Kure et al.,
2010). In contrast, LXA4 may promote an M2a and M2c MF
phenotype by modulating STAT3 (Li et al., 2011) and prolonging
the MF lifespan by inhibiting LPS-induced apoptosis via PI3K/
Akt and ERK/Nrf-2 pathways (Prieto et al., 2010). Furthermore,
our finding that LXA4 promotes aWATM1-to-M2MFpolarization
correlates with earlier reports that depletion of CD11c+ cells re-
sults in rapid normalization of obesity-induced insulin sensitivity,
paralleled by a decrease in adipose and systemic inflammation
(Patsouris et al., 2008). Similarly, u3-derived SPMs (e.g., Rvs,
protectins, andmaresins) reduce insulin resistance, increase adi-
ponectin secretion, and modulate adipose MF functions toward
a ‘‘pro-resolution phenotype’’ in genetic models of obesity
(Gonza´lez-Pe´riz and Cla`ria, 2010; Gonzalez-Periz et al., 2009;
Hellmann et al., 2011; Neuhofer et al., 2013; Ost et al., 2010).
It is important to recognize that in addition to their well-
established actions on leukocytes (Serhan, 2007), LXs affect
numerous cell types, including adipocytes (Borgeson et al.,
2012). It is therefore reasonable to ask whether LXA4-mediated
attenuation of WAT inflammation occurred through modulation
of theMF phenotype and/or via direct manipulation of the adipo-
cyte cell function. LXA4 restores TNF-a-induced impairment of
insulin signaling in normal 3T3-L1 adipocytes (Borgeson et al.,
2012). In this study, we used a similar experimental setup,
composed of murine MFs and hypertrophic adipocytes, the
latter in order to better mimic obesity (Yoshizaki et al., 2012).
The results confirmed that LXA4 may reduce inflammation by
affecting both MFs and adipocytes. We confirmed in vitro that
LXA4 shifts the MF phenotype from M1 to M2, and that this
translates to an attenuation of MF TNF-a production. LXA4 has
a direct effect on hypertrophic adipocyte IL-6 secretion;
although this effect may be overwhelmed by the strong inflam-
matory stimuli from M1 MFs. Interestingly, this in vitro system
correlated with our in vivo data, where the LXA4 primarily
affected adipose TNF-a gene expression.
The LXA4 receptor is expressed in the adipose ‘‘target tissue.’’
The murine homologs of ALX/FPR2 are Fpr2/Fpr-rs1 and Fpr3/
Fpr-rs2, and we have previously demonstrated that Fpr-rs2/
FPR3 is expressed in both the murine adipocytes and macro-
phages (Borgeson et al., 2012). Furthermore, Cla`ria et al. report
that expression of the LXA4 receptor is present in mouse WAT,
and that this expression is sustained in obese mice (Cla`ria
et al., 2012). Interestingly, they also show that the human LXA4
receptors ALX/FPR2 andGPR32 are identified in human adipose
tissue (Cla`ria et al., 2012).
In addition to attenuating WAT inflammation, LXs modulated
HFD-induced adipose autophagy. The general consensus is
that chronic obesity causes excessive activation of autophagy
in the adipose tissue, which correlates with increased cell deathhicle-treated SFD and HFD wild-type (WT) and adiponectin/ mice (n = 7).
ted, excluding the outlier identified in (F). Data are presented as mean ± SEM.
respective condition in the WT versus adiponectin/ strain are indicated as
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and adipose inflammation (Martinez et al., 2013; Stienstra et al.,
2014). In accordance with previous studies (Cummins et al.,
2014; Stienstra et al., 2014), our data show that HFD is associ-
ated with enhanced levels of autophagy in WAT, as evident
from decreased detectable p62 and LC3-II, suggesting high
autophagy flux and enhanced degradation of the proteins. Inter-
estingly, LXs restored the HFD-induced decrease in p62 and
LC3-II protein to the levels observed in lean mice. Importantly,
the LX-mediated attenuation of autophagy was independent of
mTOR and AMPK activity, and we hypothesize that LXs may
regulate autophagy by modulating the autophagic flux via regu-
lation of autophagosome maturation (fusion of autophagosomes
with lysosome). However, future studies are needed to investi-
gate the detailed molecular mechanisms involved in LX-medi-
ated regulation of autophagy and its significance in LX-mediated
attenuation of adipose inflammation. Interestingly, p62/SQSTM1
has been identified as one of the key proteins that promote lipid
metabolism and limit inflammation in the recently identified
mMe-MFs (Kratz et al., 2014). Activation of p62 results in inhibi-
tion of NF-kB and thus limits inflammation. It is therefore partic-
ularly noteworthy that LXs restore obesity-induced attenuation
of p62, as it may correlate with a restoration not only of M1/M2
phenotype, but also an anti-inflammatory mMe-MF population.
This will be the focus of future work.
Obesity is an independent risk factor for kidney disease, even
when excluding variables such as diabetes and hypertension
(Bo¨rgeson and Sharma, 2013). Additionally, obesity accelerates
the progression of pre-existing kidney disease (Mathew et al.,
2011). We have previously shown that LXA4 and BenzoLXA4
attenuate experimental tubulointerstitial fibrosis induced by uni-
lateral ureteric obstruction (Borgeson et al., 2011; Brennan et al.,
2013). LXs have also been shown to be protective in acute renal
injury, attenuating the inflammatory response to ischemia reper-
fusion injury (Bo¨rgeson and Godson, 2012; Leonard et al., 2002).
However, the potential of using LXA4 in models of obesity-
induced CKD has not previously been investigated. The present
study showed that both LXA4 and BenzoLXA4 attenuated
obesity-induced CKD, as evidenced by reduced glomerular
expansion and mesangial matrix deposition. The LXs also atten-
uated the mild tubulointerstitial fibrosis observed in this experi-
mental system. LXA4 rescued albuminuria, a cardinal sign of
kidney disease, and significantly lowered HFD-induced urine
H2O2 levels, which were used as a marker of reactive oxygen
species (ROS) and renal injury. Interestingly, renal leukocyte infil-
tration was not significantly affected by LXs in this disease
model, suggesting that the protection was not due to a direct
effect on the renal inflammatory milieu.
Obesity-induced non-alcoholic fatty liver disease (NAFLD) is
also becoming a major health problem. NAFLD ranges from
steatosis (accumulation of hepatic TGs) to non-alcoholic steato-
hepatitis (NASH or steatohepatitis, steatosis with an inflamma-
tory component). Hepatic steatosis is associated with enhanced
hepatic susceptibility to progression into irreversible forms of
liver disease (Spite et al., 2014). Other SPMs (RvE1, Protectin
D1, and D-series Rvs) attenuate obesity-induced liver disease
(Cla`ria et al., 2012; Gonzalez-Periz et al., 2009). LXA4 enhances
organ function in murine liver transplantation, attenuating serum
ALT and inducing a pro-resolving shift in cytokine production,
decreasing IFN-g while increasing IL-10 (Levy et al., 2011; Liao134 Cell Metabolism 22, 125–137, July 7, 2015 ª2015 Elsevier Inc.et al., 2013). Recent data highlight a protective effect of LXs
and other arachidonate-derived mediators in cardiovascular dis-
ease associated with increased reverse cholesterol transfer and
lower plasma LDL (Demetz et al., 2014). In our model, obesity
caused mild liver injury, as apparent by increased serum ALT,
liver weight, and TG accumulation. Interestingly, LXs attenuated
HFD-induced liver injury, as both LXA4 and BenzoLXA4 attenu-
ated serum ALT and hepatic TG deposition to baseline levels.
LXA4 significantly attenuated liver weight, which is a particularly
noteworthy finding because the total body weight was not
affected. The attenuation of hepatic TG deposition may correlate
with the restoration of hepatic expansion. However, this may not
be the sole explanation, as BenzoLXA4-induced attenuation of
hepatic TGs did not translate to altered organ weight. LXA4-
induced reduction of hepatic edemamay be an additional expla-
nation for the significant effect mediated by LXA4 on attenuation
of liver weight. Collectively, our findings suggest that LX-medi-
ated reduction of hepatic steatosis may make the liver more
resistant against additional insults. Previous research demon-
strates that an accumulation of WAT MFs and resulting adipose
inflammation correlates with liver pathology (Cancello et al.,
2006; Ix and Sharma, 2010; Tordjman et al., 2009). We thus pro-
pose that the LX-mediated restoration of theWATM1/M2 ratio is
a key mechanism of action in the reduction of liver pathology. In
line with this argument, our data reveal that LXA4 increases WAT
levels of the pro-resolving AnxA1, which is protective of NASH in
mice (Locatelli et al., 2014). Specifically, this interesting study
demonstrates that WAT MF-derived AnxA1 plays a functional
role in modulating hepatic inflammation and fibrogenesis during
NASH progression. The LXA4-mediated increase in AnxA1 is
thus likely a keymechanism of action in the observed attenuation
of liver injury.
In addition to LXA4, we evaluated the therapeutic potential of a
(1R)-stereoisomer analog (referred to as BenzoLXA4) in these
experiments. This analog differs structurally from the benzo-
analog o-(9,12)-benzo-u6-epi-LXA4 described by Sun et al.
(Sun et al., 2009) and is protective in acute inflammation and tu-
bulointerstial fibrosis (Borgeson et al., 2011; O’Sullivan et al.,
2007). It should be noted that the BenzoLXA4 analog exerted
similar actions as LXA4, although the native compound proved
more effective in the present study. Thus, the analog provides
us with valuable insights into the effect on biological activity of
modifying the triene unit of native LXA4 to a metabolically more
stable benzene ring as well as the importance of (R)-stereo-
chemistry at the benzylic carbinol center, which will aid future
analog design.
The adiponectin/AMPK axis is implicated in obesity-induced
liver and kidney pathology (Mathew et al., 2011; Sharma et al.,
2008). Previous work demonstrates that LXA4 increases adipo-
nectin in adipose explants (Cla`ria et al., 2012) and is present in
human adipose tissue (Cla`ria et al., 2013) and urine (Sasaki
et al., 2015), and herein we observed a trend toward increased
WAT adiponectin production in LX-treated mice (Figure 1D).
Therefore, we hypothesized that LXs may mediate protection
in our obesity model via induction of adiponectin in WAT. To
explore this possible mechanism of action, we carried out the
experimental design in both WT and adiponectin/ mice. The
assumption was that if our hypothesis was correct, the LX-medi-
ated protection would not be observed in the KO strain. The
LX-mediated restoration of albuminuria was evident in both WT
and adiponectin/mice, although LXs displayed increased abil-
ity to attenuate HFD-induced urine H2O2 production in the KO
strain. Furthermore, the in vitro data show that neither LXA4
nor BenzoLXA4 induced adiponectin production in hypertrophic
3T3-L1 adipocytes. In addition, the LXs did not rescue MF-
induced attenuation of adiponectin production in the adipocytes.
Collectively, the data thus show that LX-mediated attenuation of
obesity-induced disease is adiponectin independent in this
model of HFD-induced renal and liver injury. In relation to our
initial observation that LXs caused a trend toward increased
WAT adiponectin production, this may simply be due to an
improved general health of these mice, rather than being a direct
mediator of LX’s beneficial effects.
LXs did not mediate protection via enhancing glucose toler-
ance in the WT animals, indicating that the mechanism of action
did not involve improved pancreatic insulin function. However,
both LXA4 and BenzoLXA4 reduced GTT 120 min post-injection
(p < 0.05) in the KO mice, although the animals still remained
significantly more insulin resistant compared to lean mice.
LXA4 also reduced fasting glucose in the adiponectin
/ strain,
suggesting that LXA4 may exert some modulation of insulin
resistance.
As the LXA4-mediated protection appeared enhanced in the
KO strain, we measured endogenous LXA4 production in the
adipose tissue of the SFD- and HFD-treated groups. Obese
adiponectin/ mice expressed significantly more endogenous
LXA4 when challenged with HFD. Thus, it is plausible that in con-
ditions of adiponectin deficiency there is a compensatory
response to further increase LX production due to enhanced
inflammation and the other arachidonic acid (AA)-derived prod-
ucts. Further exogenous administration of LXsmay be necessary
to restore insulin sensitivity. The regulation of LXs by adiponectin
is worthy of future studies. Whether LXs may have an effect to
improve insulin sensitivity and lower blood glucose in other
models of diabetes remains to be tested.
In conclusion, these results indicate that LXs have therapeutic
potential in obesity-induced pathologies, such as liver disease
and CKD. LXA4 likely mediates protection via reducing adipose
inflammation and modulation of WAT MF phenotype. Interest-
ingly, LXs reversed HFD-induced adipose autophagy, which
has been linked to obesity-induced disease. LX-mediated pro-
tection was independent of systemic adiposity and glucose
tolerance. Moreover, the LX-mediated actions were adiponectin
independent in this system. Collectively, these results demon-
strate the potential of using SPMs, such as LXA4 and LX-stable
analogs, to protect from obesity-induced pathologies.EXPERIMENTAL PROCEDURES
Detailed protocols are described in Supplemental Experimental Procedures.
In Vivo Obesity Study
C57BL/6J (n = 10) and C57BL/6J adiponectin/ mice (n = 7) (Jackson Labo-
ratory) were fed a SFD (10% fat) or a HFD (60% fat) for 12 weeks. Vehicle (1%
ethanol), LXA4 (5 ng/g), or BenzoLXA4 (1.7 ng/g) were given as 100 ml intraper-
itoneal (i.p.) injections three times per week between weeks 5 and 12. Vehicle
does not increase baseline WAT inflammation (Qin et al., 2014). LXA4 (5(S)-
6(R)-15(S)-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid) was bought
from EMD Millipore, and (1R)-BenzoLXA4 was synthesized by P.J.G.(O’Sullivan et al., 2007). Insulin-stimulated glucose tolerance, micro-albumin-
uria, and urinary H2O2 were assessed 1 week prior to sacrifice, and organs
were harvested under isoflurane sedation. All animal procedures were
approved by the Institutional Animal Care and Use Committee (IACUC).
Flow Cytometry Analyses
Leukocytes isolated from homogenized WAT and kidneys were stained and
characterized by flow cytometry as pan-MFs (F4/80PEhiCD11bAPChi), M1
MFs (CD11c+PerCPcy5.5 of CD45+F480hiCD11bhi cells), or M2 MFs (CD206+
FITC of CD45+F480hiCD11bhi cells) (Figure S2). B cells (CD19+) and T cells
(CD4+ versus CD8+) were also identified.
Lipid Mediator Lipidomics
Endogenous LXA4 production was determined in snap-frozen WAT from SFD
and HFD animals (n = 7), using targeted LC-MS/MS-based lipidomics (Colas
et al., 2014). One outlier was identified by the ROUT method in the
adiponectin/ HFD group (Figure 6F) and excluded in the paired ‘‘Fold in-
crease’’ analyses (Figure 6G).
Immunohistochemistry
Renal glomerular expansion and matrix deposition were assessed by Periodic
Acid-Schiff and tubulointerstitial fibrosis by Sirius Red staining. Livers and
WAT were stained for H&E, ki67, and F4/80+ MFs. WAT p62 and LC3-II pro-
teins were detected by immunofluorescence. Staining was quantified by color
deconvolution algorithms (Aperio Software).
Protein Analyses
WAT protein (40 mg) was immunoblotted on a 16% SDS-PAGE gel and trans-
ferred onto 0.2 mmPVDFmembranes. Proteins identified as LC3, p62, pmTOR,
mTOR, pAMPK, AMPK, AnxA1, and b-Actin were quantified using Adobe
Photoshop.
Adipose and Liver mRNA Expression
RNA was isolated from tissues homogenized in TRIzol. Relative TNF-a, IL-6,
and IL-10mRNA expression was analyzed by theDDCTmethod using TaqMan
primer/probe (Life Technologies) and normalized to 18S.
Liver Function Analyses
Liver tissue (100 mg) suspended in 3 M KOH (in 65% EtOH) was incubated at
70C for 1 hr, to activate digestion, and diluted 1:3 with 2 M Tris-HCl (pH 7.5).
Subsequently, ALT, TGs, and cholesterol E were analyzed in both liver extracts
and serum.
In Vitro Experiments
J774 MFs were incubated with vehicle (0.1% ethanol), LXA4 (1 nM), or
BenzoLXA4 (10 pM) for 16 hr. Supernatants were collected, andMF phenotype
was determined by flow cytometry as M1 (CD11+) versus M2 (CD206+).
Serum-starved hypertrophic 3T3-L1 adipocytes were treated with vehicle,
LXA4 (1 nM), or BenzoLXA4 (10 pM) for 24 hr. Alternatively, adipocytes were
treated with the MF-conditioned supernatants for 24 hr. Adipocyte superna-
tant TNF-a, IL-6, and adiponectin levels were assessed by ELISA.
Statistical Analyses
The in vivo study was calculated to an experimental power of 80%. Assuming
Gaussian distribution, ANOVA with Bonferroni correction was used to assess
statistical significance (p < 0.05). Data are presented as mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.cmet.2015.05.003.
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